Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Phase II results presented on Perifosine for prostate cancer
June 17th, 2005
AEterna Zentaris, Inc., (AEZ; AEZS) announced that its North American partner for perifosine, Keryx Biopharmaceuticals, Inc., (KERX) disclosed that data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, demonstrated the tolerability and potential efficacy of perifosine in the treatment of patients with biochemically recurrent hormone-sensitive prostate cancer (HSPC). This study was conducted by a consortium of cancer centers under the leadership of the University of California, Davis pursuant to a Collaborative Research and Development Agreement (CRADA) between Keryx and the National Cancer Institute. Perifosine is...
Source: Drug Week (2005-06-17)
|
